home / stock / rgedf / rgedf news
AbbVie (NYSE:ABBV) said Health Canada approved Vraylar (cariprazine) as a standalone therapy for the acute management of manic, mixed, and depressive episodes linked with bipolar 1 disorder in adults, and to treat schizophrenia in adults. Bipolar 1 is a mental disorder characterized by e...
Johnson & Johnson (JNJ) has agreed to divest ex-U.S. rights to unit Janssen Pharmaceuticals' Evra (norelgestromin, ethinyl estradiol) transdermal contraceptive patch to Gedeon Richter (RGEDF) for $263.5M.Richter Executive Chairman Erik Bogsch says, "This agreement is considered as a furth...
Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...